Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy

Livermore, 2009, Has the era of untreatable infections arrived?, J Antimicrob Chemother, 64, i29, 10.1093/jac/dkp255 Zhanel, 2014, Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli, Drugs, 74, 31, 10.1007/s40265-013-0168-2 Cluck, 2015, Ceftolozane–tazobactam: a new-generation cephalosporin, Am J Heal Pharm, 72, 2135, 10.2146/ajhp150049 Moya, 2010, Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients, Antimicrob Agents Chemother, 54, 1213, 10.1128/AAC.01104-09 Fraile-Ribot, 2018, Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa, J Antimicrob Chemother, 73, 658, 10.1093/jac/dkx424 Haidar, 2017, Ceftolozane–tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance, Clin Infect Dis, 65, 110, 10.1093/cid/cix182 Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018, 1 Magiorakos, 2012, Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect, 18, 268, 10.1111/j.1469-0691.2011.03570.x Fraile-Ribot, 2017, In vivo emergence of resistance to novel cephalosporin–β-Lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 β-Lactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa, Antimicrob Agents Chemother, 61, 1, 10.1128/AAC.01117-17 Kaufmann, 1998, Pulsed-field gel electrophoresis, vol. 15, 33 Curran, 2004, Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa, J Clin Microbiol, 42, 5644, 10.1128/JCM.42.12.5644-5649.2004 Cabot, 2014, Pseudomonas aeruginosa ceftolozane–tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC, Antimicrob Agents Chemother, 58, 3091, 10.1128/AAC.02462-13 van Duin, 2016, Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations, Clin Infect Dis, 63, 234, 10.1093/cid/ciw243 Bassetti, 2019, Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience, Int J Antimicrob Agents, 53, 408, 10.1016/j.ijantimicag.2018.11.001 Escolà-Vergé, 2018, Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections, Infection, 46, 461, 10.1007/s15010-018-1133-5 Cabot, 2012, Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones, Antimicrob Agents Chemother, 56, 6349, 10.1128/AAC.01388-12 MacVane, 2017, Emergence of ceftolozane–tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation, Antimicrob Agents Chemother, 61, 10.1128/AAC.01183-17 Boulant, 2019, A 2.5-year within-patient evolution of Pseudomonas aeruginosa isolates with in vivo acquisition of ceftolozane–tazobactam and ceftazidime–avibactam resistance upon treatment, Antimicrob Agents Chemother, 63, 10.1128/AAC.01637-19 Barnes, 2018, Deciphering the evolution of cephalosporin resistance to ceftolozane tazobactam in Pseudomonas aeruginosa, mBio, 9, 10.1128/mBio.02085-18 Poirel, 2018, Acquisition of extended-spectrum β-lactamase GES-6 leading to resistance to ceftolozane–tazobactam combination in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 63, 10.1128/AAC.01809-18 Khan, 2019, Extensively drug-resistant Pseudomonas aeruginosa ST309 harboring tandem Guiana extended spectrum β-Lactamase enzymes: a newly emerging threat in the United States, Open Forum Infect Dis, 6, 10.1093/ofid/ofz273 Arca-Suárez, 2019, Challenging antimicrobial susceptibility and evolution of resistance (OXA-681) during treatment of a Pseudomonas aeruginosa ST175 clone long-term nosocomial infection, Antimicrob Agents Chemother, 63, 10.1128/AAC.01110-19 Mack, 2019, A standard numbering scheme for class C β-lactamases, Antimicrob Agents Chemother, 10.1128/AAC.01841-19